- Record: found
- Abstract: not found
- Article: not found
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
A. Gupta ,
S. Love ,
A. Schuh ,
M. Shanyinde ,
J.M. Larkin ,
R. Plummer ,
P.D. Nathan ,
S. Danson ,
C.H. Ottensmeier ,
P. Lorigan ,
L. Collins ,
A. Wise ,
R. Asher ,
R. Lisle ,
M.R. Middleton
May 2014
May 2014
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib,
a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation
status, and combination with docetaxel has demonstrated synergy in xenograft models.
The aim of this study was to assess the efficacy and safety of selumetinib plus docetaxel
as first-line treatment in patients with wild-type BRAF advanced melanoma.